Stephen Anindo connects companies at a turning point with the specialists they need next: recruiters for a hiring push, wealth advisors for a founder exit, life-science partners for a biotech raise or deal.
Public funding, hiring and deal data across the three lanes, updated as it publishes.
- →London's Prevalent AI raises £16.1M to scale go-to-market and deepen its leadership team: August 2026
- →Balderton leads Itoflow's $2.5M pre-seed to expand engineering and quant research teams: August 2026
- →Durham biotech Magnitude Biosciences raises £1.3M and plans to recruit additional staff: September 2026
- →UK permanent placements rose in August, the first rise since September 2022: KPMG and REC
Sourced from funding announcements and the KPMG and REC UK Report on Jobs, August to September 2026.
No deal to point at yet, so here’s exactly what I put in motion.
- Company hiring → specialist recruiter When a company raises, expands or brings in a new leader, the hiring plan is already written. I put a recruiter who knows that exact specialism in front of the hiring lead before the roles hit every job board.
- Founder at an exit → wealth and exit advisors When a founder sells, steps back or takes money off the table, the next decisions are about what to do with it. I introduce the advisors and family offices who work with exactly that situation, early.
- Biotech raising or partnering → life-science specialists When a biotech raises, starts a trial or signs a licensing deal, it needs clinical staff, a CRO or a BD advisor fast. I route the specialists who already know the science.
I’m working alongside myoProcess, a vetted B2B partner trusted across $1B+ in transactions, while I route my first introductions. My first closed match replaces this paragraph.
What I see in this market that outsiders miss.